# Astellas Pharma Inc. (ALPMY)

> Source: Nexqual · https://nexqual.com/ALPMY · data as of 2026-10-23 17:04 UTC · cite as "Nexqual, Astellas Pharma Inc. (ALPMY), nexqual.com/ALPMY" · informational, not investment advice.

**Price:** USD 15.94 (+0.95% today) · US market open, as of October 23, 2026 at 17:04 UTC; quotes may be delayed. Prev close 15.79 · day 15.9–15.94 · 52w 10.05–17.35 · market cap $28.6B · PNK

## Key facts
- Analysts: Buy (mean 2.00 on a 1–5 scale) (1 analysts), mean target USD 17.4 (range 17.4–17.4).
- Total return with dividends: 1Y +48.8% vs S&P 500 +14.4%; 5Y -1.0% vs S&P 500 +77.0%.
- Next earnings: 2026-11-04, EPS estimate USD —, revenue estimate $594B.

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 1 analysts; mean target USD 17.4 (low 17.4, high 17.4).

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | +48.8% | -1.0% |
| S&P 500 (SPY) | +14.4% | +77.0% |
| Per year | +48.9% | -0.2% |
| Volatility (annualized) | 29.8% | 25.6% |
| Max drawdown | -22.3% (Apr 2026→Jul 2026) | -47.0% (Nov 2021→Apr 2025) |

## Peers (Drug Manufacturers - General)
BIIB (Biogen Inc.) USD 250.37 -1.37% · SNY (Sanofi) USD 41.5 -1.11% · GSK (GSK plc) USD 50.63 -1.13% · BMY (Bristol-Myers Squibb Company) USD 61.56 -2.29% · GRFS (Grifols, S.A.) USD 7.54 +1.14% · PFE (Pfizer, Inc.) USD 29.98 -1.46%

## More
Full page: https://nexqual.com/ALPMY · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | — | — | — | $594.09B | — |
| Next quarter (ends 2026-12-31) | — | — | — | $616.88B | — |
| Current fiscal year (ends 2027-03-31) | $1.23 | $1.31 | -6.4% | $2.37T | 1 |
| Next fiscal year (ends 2028-03-31) | $1.14 | $1.17 | -3.0% | $2.21T | 1 |